Amgen vs Biogen
AMGN and BIIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and BIIB compare
Amgen is the larger company, worth 6.7 times as much as Biogen ($252B against $37.5B).
On earnings, Amgen is cheaper: it trades at 28.9× trailing earnings, against 44.9× for Biogen.
Amgen grew revenue faster over the last twelve months (9.1% versus 0.31% for Biogen).
Amgen keeps more of each dollar of sales as profit, with a net margin of 23.0% compared with 8.3% at Biogen.
Amgen pays a dividend yielding 2.1%; Biogen does not pay one.
Amgen scores higher on the StockData Score (17 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | BIIB |
|---|---|---|
| Size and price | ||
| Market cap | $252B | $37.5B |
| Share price | $466.01 | $253.62 |
| Change, 1 year | 59.7% | 71.5% |
| Change, 5 years | 118% | −9.0% |
| Beta (5Y) | 0.42 | 0.51 |
| Employees | 32K | 7,500 |
| StockData Score | ||
| Total score | 17 (better) | 4 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 6 (better) | 1 |
| Health score | 2 | 2 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 28.9× (better) | 44.9× |
| P/S | 6.6× | 3.7× (better) |
| P/B | 21.6× | – |
| EV/EBITDA | 20.9× | 16.9× (better) |
| P/FCF | 24.8× | 13.9× (better) |
| PEG | 5.24 | – |
| FCF yield | 4.0% | 7.2% (better) |
| Fair value | $334.49 | $157.62 |
| Margin of safety | −39.3% (better) | −60.9% |
| Growth | ||
| Revenue growth (TTM) | 9.1% (better) | 0.31% |
| Revenue growth, 5Y average | 7.6% (better) | −6.0% |
| Net income growth (TTM) | 32.1% (better) | −45.5% |
| EPS growth (TTM) | 31.6% (better) | −46.0% |
| EPS growth, 5Y average | 2.9% (better) | −18.7% |
| Profitability | ||
| Gross margin | 69.5% | 74.0% (better) |
| Operating margin | 30.0% | – |
| Net margin | 23.0% (better) | 8.3% |
| FCF margin | 26.7% | 26.9% (better) |
| Return on equity | 91.5% | – |
| Return on invested capital | 17.6% | – |
| Financial health | ||
| Debt / equity | 4.90 | – |
| Net debt / EBITDA | 3.07 | – |
| Interest coverage | 4.3× | – |
| Current ratio | 1.37 | 1.87 (better) |
| Altman Z-score | 2.39 | 3.05 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | – |
| Payout ratio | 60.4% | – |
| Years of dividend growth | 9 | – |
| Dividend growth, 5Y average | 8.0% | – |
| Shareholder yield | 2.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 82.7% | 96.3% |
| Held by insiders | 0.21% | 0.21% |
| Insider net buying, 12 months | −$29.3M | −$905K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.6% | 4.0% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.